CD276 and melanoma: B7-H3 blocking with mAbs has been shown to increase CD8+ T-cell and NK-cell tumor infiltration, reduce tumor growth, and prolong survival in mouse models of hematopoietic cancers, ovarian cancer (37), melanoma (77) and CRC (78).